Study to Repurpose MS Drug Shows CMT1X Benefit

In a TIN-sponsored study newly published in the May issue of Neuromuscular Disorders (https://doi.org/10.1016/j.nmd.2025.105345) the Martini group now reports that CMT1X mice treated with Fingolimod showed improved nerve function, and the drug positively changed some motor functions (balance), as well as grip strength. The results suggest that Fingolimod, or more advanced drugs of this class that are available for the treatment of multiple sclerosis, may be a treatment option to ease the disease burden in severe cases of CMT1X. The approach may also be of use in other Type 1 CMT’s in which immune system dysfunction is similarly involved.